---
ver: rpa2
title: 'Cinepro: Robust Training of Foundation Models for Cancer Detection in Prostate
  Ultrasound Cineloops'
arxiv_id: '2501.12331'
source_url: https://arxiv.org/abs/2501.12331
tags:
- cancer
- ultrasound
- data
- prostate
- cinepro
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: This paper introduces Cinepro, a framework for training foundation
  models on weakly labeled prostate ultrasound cineloops to detect cancer. The key
  innovations are an involvement-aware loss function that incorporates pathology-reported
  cancer tissue proportions to handle label noise, and a cine-series augmentation
  strategy that leverages temporal data across multiple frames.
---

# Cinepro: Robust Training of Foundation Models for Cancer Detection in Prostate Ultrasound Cineloops

## Quick Facts
- arXiv ID: 2501.12331
- Source URL: https://arxiv.org/abs/2501.12331
- Reference count: 0
- Primary result: Cinepro achieves 77.1% AUROC and 83.8% balanced accuracy on multi-center prostate ultrasound cineloops using weakly labeled data.

## Executive Summary
Cinepro introduces a framework for training foundation models on weakly labeled prostate ultrasound cineloops to detect cancer. The method combines an involvement-aware loss function that incorporates pathology-reported cancer tissue proportions with a temporal augmentation strategy using multiple frames. Cinepro achieves state-of-the-art performance with 77.1% AUROC and 83.8% balanced accuracy, surpassing existing benchmarks on multi-center data.

## Method Summary
Cinepro adapts MedSAM's foundation model architecture for prostate cancer detection using weakly supervised learning. The method employs an involvement-aware MSE loss (iMSE) that minimizes the difference between model predictions and pathology-reported cancer involvement proportions within needle regions. A cine-series augmentation strategy generates weak and strong views of the same tissue using single-frame and temporally averaged multi-frame inputs respectively. The model is trained with shared weights across both views, producing robust predictions that outperform traditional binary classification approaches.

## Key Results
- AUROC of 77.1% on multi-center prostate ultrasound cineloops
- Balanced accuracy of 83.8% exceeding existing benchmarks
- Sensitivity at 20%/40%/60% specificity: 85.3%/89.7%/95.2%
- MedSAM backbone with iMSE loss outperforms SAM and UNet baselines

## Why This Works (Mechanism)

### Mechanism 1
Training with continuous involvement values rather than binary labels may reduce the impact of coarse annotation noise. The iMSE loss minimizes the squared difference between the model's average prediction in the needle region and the pathology-reported cancer proportion (0–1 scale). This provides graded supervision instead of forcing the model to fit binary cancer/benign labels that may not reflect the true tissue distribution within the sampled region. Core assumption: pathology-reported involvement values contain meaningful signal about the proportion of cancer within each core. Evidence anchors: integrating proportion of cancer tissue reported by pathology into loss function; LiMSE formula explicitly shows regression to involvement values. Break condition: if involvement values exhibit high inter-pathologist variability or systematically misrepresent actual cancer distribution.

### Mechanism 2
Combining weakly augmented single frames with strongly augmented temporal averages may improve robustness to acquisition noise. The model receives two views of the same tissue: a weakly augmented initial frame (simple translations) and a strongly augmented average of 199 frames (brightness jitter, speckle noise, line/pixel cuts). The shared-weight models are trained to produce consistent predictions, with a confidence threshold filtering low-certainty pixels before weighted averaging. Core assumption: temporal averaging reduces frame-specific noise while preserving cancer-related signal. Evidence anchors: leverages temporal data across multiple frames to apply robust augmentations; describes weak-strong augmentation pipeline and shared-weight training. Break condition: if meaningful diagnostic information varies across frames, averaging may remove discriminative signal rather than noise.

### Mechanism 3
MedSAM's pre-trained representations may transfer better to whole-image prostate ultrasound analysis than models trained from scratch or generalist foundation models. MedSAM's ViT encoder (pre-trained on medical images) produces embeddings that capture spatial relationships across the entire image. The mask decoder is fine-tuned to predict cancer involvement rather than segmentation masks, leveraging the encoder's ability to represent tissue context. Core assumption: medical image pre-training provides representations that capture relevant tissue texture patterns. Evidence anchors: MedSAM + iMSE achieves 75.2% AUROC vs. SAM + iMSE at 71.6% and UNet + iMSE at 68.8%; supports foundation model utility in PCa tasks. Break condition: if pre-training domain lacks transferable features for cancer detection texture discrimination, fine-tuning may underfit.

## Foundational Learning

- **Concept: Weak Supervision with Proportion Labels**
  - Why needed here: Pixel-level cancer annotations are unavailable; only coarse biopsy-core pathology reports exist. Understanding how to train on proportion/extent labels rather than dense masks is essential.
  - Quick check question: Can you explain why a regression loss to involvement values might be more robust than treating each pixel as cancer/benign based on the core label?

- **Concept: Foundation Model Adaptation**
  - Why needed here: The method adapts MedSAM (a segmentation model) to a classification-like task. Understanding what transfers (spatial reasoning, texture encoding) vs. what must change (decoder head, loss function) is critical.
  - Quick check question: What components of MedSAM are frozen vs. fine-tuned, and why might the mask decoder need modification for cancer involvement prediction?

- **Concept: Weak-Strong Augmentation Consistency**
  - Why needed here: The cine-series augmentation is inspired by semi-supervised consistency training. Understanding how two views of the same input enforce stable predictions helps diagnose training dynamics.
  - Quick check question: If the model overfits to the weakly augmented view but fails on the strongly augmented view, what does this suggest about the augmentation strength or model capacity?

## Architecture Onboarding

- **Component map:** Input (1024×1024 B-mode frames) -> MedSAM ViT encoder (~90M params) -> MedSAM mask decoder (~6M params) -> 256×256 prediction map -> iMSE loss over needle-prostate intersection

- **Critical path:** Load pre-trained MedSAM weights → Generate weak (Xw) and strong (Xs) augmented views → Forward pass through shared-weight encoder + decoder → Apply confidence threshold to weak output → Weighted average of weak and strong predictions → Compute iMSE against ground-truth involvement → Backpropagate and update

- **Design tradeoffs:** Confidence threshold (τ) higher values remove more low-confidence pixels but may discard useful signal; paper does not specify optimal value. Weak/strong weighting (γw, γs) controls balance between clean and augmented views; requires tuning. Foundation model choice: MedSAM outperforms SAM but has larger memory footprint; UNet is faster but underperforms

- **Failure signatures:** High training loss with low validation AUROC may indicate label noise overwhelming signal or augmentation too aggressive. Good AUROC but poor sensitivity at high specificity: model may be overly conservative; check confidence threshold and loss weighting. Disparity between weak and strong view performance: augmentation strategy may be mismatched to ultrasound characteristics

- **First 3 experiments:** 1) Baseline establishment: Train MedSAM with standard MaskCE loss on the dataset without involvement-aware training or cine augmentation; record AUROC and sensitivity metrics. 2) Ablation of iMSE: Replace MaskCE with iMSE loss while holding augmentation constant; quantify improvement from involvement-aware supervision alone. 3) Augmentation impact: Add cine-series weak-strong augmentation to the iMSE setup; compare against naive translation-only augmentation to isolate temporal averaging effects

## Open Questions the Paper Calls Out
- Future work should focus on integrating the proposed method in a larger study to further improve generalization and robustness.

## Limitations
- Current evaluation uses data from only two clinical centers (KHSC and VGH) with a single ultrasound system (BK3500), limiting assessment of broader applicability.
- The preprocessing section explicitly states that data containing motion and acoustic shadowing artifacts are excluded, indicating the model's behavior on such clinically realistic data remains untested.
- The results note that iMSE leads to superior cancer detection but comes at the cost of increased false positives for SAM-based models, suggesting a remaining trade-off to optimize.

## Confidence
- **High confidence**: AUROC (77.1%) and balanced accuracy (83.8%) are directly reported from the paper's experiments and represent the primary quantitative claims.
- **Medium confidence**: The mechanism of iMSE loss improving robustness relies on implicit assumptions about pathology data quality that are not empirically tested.
- **Low confidence**: The specific contribution of temporal augmentation cannot be isolated from other methodological changes in the presented experiments.

## Next Checks
1. Conduct an ablation study comparing iMSE loss against standard classification loss while holding all other factors constant to isolate the involvement-aware supervision effect.
2. Compare the cine-series augmentation strategy against a single-frame augmentation baseline to quantify the specific benefit of temporal averaging.
3. Analyze the correlation between pathology-reported involvement values and ground-truth cancer extent (if available) to validate the reliability of the supervision signal.